The anaphase-promoting complex/cyclosome is an E3 ubiquitin ligase for Mdm2

Cell Cycle

Volumn 13, Issue 13, 2014, Pages 2101-2109

  He, Yizhou ^a   Tollini, Laura ^a   Kim, Tae Hyung ^a   Itahana, Yoko ^a,c   Zhang, Yanping ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

APC C; E3; Mdm2; P53; Ubiquitin

Indexed keywords

ANAPHASE PROMOTING COMPLEX SUBUNIT 2; PROTEASOME; PROTEIN MDM2; PROTEIN P53; RNA; MDM2 PROTEIN, HUMAN;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSCRIPTION; HELA CELL LINE; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RNA INTERFERENCE; SENESCENCE; STRESS; UBIQUITINATION; ANIMAL; CARCINOGENESIS; GENETICS; METABOLISM; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; APC2 SUBUNIT, ANAPHASE-PROMOTING COMPLEX-CYCLOSOME; CARCINOGENESIS; CELL LINE, TUMOR; HUMANS; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 84903793859     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.29106     Document Type: Article

References (29)

1. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010; 24:1580-9; PMID:20679392; http://dx.doi.org/10.1101/gad.1941710
2. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-45; PMID:1535557; http://dx.doi.org/10.1016/ 0092-8674(92)90644-R
3. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857-60; PMID:8479525; http://dx.doi.org/10.1038/362857a0
4. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25-7; PMID:9450543; http://dx.doi.org/10.1016/S0014-5793(97)01480-4
5. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303; PMID:9153396; http://dx.doi.org/10.1038/387299a0
6. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006; 21:307-15; PMID:16455486; http://dx.doi.org/10.1016/j.molcel.2006.01.020
7. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9; PMID:9153395; http://dx.doi.org/10.1038/387296a0
8. Lahav G. Oscillations by the p53-Mdm2 feedback loop. Adv Exp Med Biol 2008; 641:28-38; PMID:18783169; http://dx.doi.org/10.1007/978-0-387-09794-7-2
9. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild-type p53 activity. EMBO J 1993; 12:461-8; PMID:8440237
10. Juven T, Barak Y, Zauberman A, George DL, Oren M. Wild-type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 1993; 8:3411-6; PMID:8247544
11. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci U S A 1993; 90:11623-7; PMID:8265599; http://dx.doi.org/10.1073/pnas.90.24.11623
12. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275:8945-51; PMID:10722742; http://dx.doi.org/10.1074/jbc.275.12.8945
13. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 2000; 19:1473-6; PMID:10723139; http://dx.doi.org/10.1038/sj.onc.1203464
14. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindström MS, Bhat KP, Godfrey VL, Evan GI, Zhang Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007; 12:355-66; PMID:17936560; http://dx.doi.org/10. 1016/j.ccr.2007.09.007
15. Clegg HV, Itahana K, Zhang Y. Unlocking the Mdm2-p53 loop: ubiquitin is the key. Cell Cycle 2008; 7:287-92; PMID:18235222; http://dx.doi.org/10.4161/cc. 7.3.5358
16. Inuzuka H, Tseng A, Gao D, Zhai B, Zhang Q, Shaik S, Wan L, Ang XL, Mock C, Yin H, et al. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell 2010; 18:147-59; PMID:20708156; http://dx.doi.org/10.1016/j.ccr.2010.06.015
17. Xu C, Fan CD, Wang X. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase. Oncogene 2014; PMID:24413081; http://dx.doi.org/10.1038/onc.2013.557
18. Uldrijan S, Pannekoek WJ, Vousden KH. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J 2007; 26:102-12; PMID:17159902; http://dx.doi.org/10.1038/sj.emboj.7601469
19. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127:1323-34; PMID:17182091; http://dx.doi.org/10.1016/j.cell.2006.12.007
20. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009; 78:399-434; PMID:19489725; http://dx.doi.org/10.1146/annurev. biochem.78.101807.093809
21. Gu L, Ying H, Zheng H, Murray SA, Xiao ZX. The MDM2 RING finger is required for cell cycle-dependent regulation of its protein expression. FEBS Lett 2003; 544:218-22; PMID:12782320; http://dx.doi.org/10.1016/S0014-5793(03) 00502-7
22. Peters JM. The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 2006; 7:644-56; PMID:16896351; http://dx.doi.org/10.1038/nrm1988
23. Thornton BR, Ng TM, Matyskiela ME, Carroll CW, Morgan DO, Toczyski DP. An architectural map of the anaphase-promoting complex. Genes Dev 2006; 20:449-60; PMID:16481473; http://dx.doi.org/10.1101/gad.1396906
24. Yu H. Cdc20: a WD40 activator for a cell cycle degradation machine. Mol Cell 2007; 27:3-16; PMID:17612486; http://dx.doi.org/10.1016/j.molcel.2007.06. 009
25. Landers JE, Haines DS, Strauss JF 3rd, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994; 9:2745-50; PMID:8058341
26. Forslund A, Zeng Z, Qin LX, Rosenberg S, Ndubuisi M, Pincas H, Gerald W, Notterman DA, Barany F, Paty PB. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers. Mol Cancer Res 2008; 6:205-11; PMID:18314481; http://dx.doi.org/10.1158/1541-7786.MCR-07-0239
27. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005; 6:229-39; PMID:15811618; http://dx.doi.org/10.1016/S1470-2045(05)70094-2
28. Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh DC, Hathaway N, Dimova N, Cuny GD, King RW. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell 2010; 18:382-95; PMID:20951947; http://dx.doi.org/10.1016/j. ccr.2010.08.010
29. Sambrook J, Russell DW. Calcium-phosphatemediated Transfection of Eukaryotic Cells with Plasmid DNAs. CSH Protoc 2006; 2006.